RT Journal Article
SR Electronic
T1 Current maintenance treatment of chronic obstructive pulmonary disease in China
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P4108
VO 44
IS Suppl 58
A1 Kewu Huang
A1 Chen Wang
A1 Jiangna Han
A1 Jinping Zheng
A1 Lu Dai
A1 INTACT Study Investigators
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P4108.abstract
AB Background: Treatment with long-acting bronchodilators is recommended to control symptoms, reduce exacerbations and improve quality of life in COPD, according to the GOLD 2011 recommendations. In China, the patterns of pharmacological treatment in COPD patients are not known yet.Aims:We investigated the current status of COPD maintenance treatments in China.Methods: 1,634 patients with spirometry diagnosis of COPD from 83 hospitals covering 17 provinces in China have so far been enrolled in the ongoing INTACT study (Indacaterol on Chronic Obstructive Pulmonary Disease maintenance treatment in China). The participants had extensive interviews concerning clinical and demographic data, symptoms as assessed by the mMRC and the CAT, exacerbation history, physician-diagnosed comorbidities, and maintenance medications used at home. Patients were assigned to the GOLD December 2011 groups A, B, C, and D.Results: 10.3% of the overall population was GOLD A; 21% B; 8.4% C and 60.3% D. The current status of COPD maintenance treatments in China are shown below. In GOLD A and GOLD B, 47.6% and 48.5% patients were on ICS/LABA; 23.1% and 25.4% patients triple.View this table:Conclusions: COPD treatment in this sample did not follow the GOLD 2011 recommendations, particularly in A, B, and C patients.